Q1 Earnings Estimate for Biohaven Issued By Leerink Partnrs

Biohaven Ltd. (NYSE:BHVN) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Biohaven in a research note issued to investors on Sunday, April 13th. Leerink Partnrs analyst M. Goodman forecasts that the company will post earnings per share of ($1.79) for the quarter. The consensus estimate for Biohaven’s current full-year earnings is ($8.90) per share. Leerink Partnrs also issued estimates for Biohaven’s Q2 2025 earnings at ($1.82) EPS, Q3 2025 earnings at ($1.84) EPS and Q4 2025 earnings at ($1.55) EPS.

Several other analysts have also recently weighed in on BHVN. JPMorgan Chase & Co. decreased their price objective on shares of Biohaven from $72.00 to $68.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft set a $60.00 price target on Biohaven and gave the company a “buy” rating in a report on Thursday, March 20th. Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 price objective on shares of Biohaven in a research note on Tuesday, March 4th. Morgan Stanley lowered their target price on Biohaven from $69.00 to $63.00 and set an “overweight” rating for the company in a research note on Friday, March 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $54.00 price target on shares of Biohaven in a research report on Tuesday, March 4th. Fourteen analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Biohaven has a consensus rating of “Buy” and an average price target of $62.77.

Biohaven Stock Up 9.2 %

Shares of Biohaven stock opened at $20.41 on Wednesday. Biohaven has a 12-month low of $15.79 and a 12-month high of $55.70. The stock has a market capitalization of $2.08 billion, a P/E ratio of -2.18 and a beta of 1.33. The company has a 50-day simple moving average of $28.88 and a 200 day simple moving average of $38.78.

Biohaven (NYSE:BHVN) last released its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.29).

Hedge Funds Weigh In On Biohaven

Several hedge funds have recently added to or reduced their stakes in the stock. Teacher Retirement System of Texas increased its stake in shares of Biohaven by 31.6% in the 4th quarter. Teacher Retirement System of Texas now owns 23,320 shares of the company’s stock valued at $871,000 after acquiring an additional 5,600 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Biohaven by 9.1% during the fourth quarter. Bank of New York Mellon Corp now owns 295,078 shares of the company’s stock valued at $11,021,000 after purchasing an additional 24,703 shares during the period. JPMorgan Chase & Co. increased its stake in Biohaven by 85.4% in the third quarter. JPMorgan Chase & Co. now owns 809,448 shares of the company’s stock valued at $40,448,000 after purchasing an additional 372,737 shares in the last quarter. American Century Companies Inc. raised its holdings in Biohaven by 9.5% in the fourth quarter. American Century Companies Inc. now owns 558,761 shares of the company’s stock worth $20,870,000 after purchasing an additional 48,286 shares during the period. Finally, Alliancebernstein L.P. boosted its position in shares of Biohaven by 6.6% during the fourth quarter. Alliancebernstein L.P. now owns 96,236 shares of the company’s stock worth $3,594,000 after purchasing an additional 5,951 shares in the last quarter. Institutional investors and hedge funds own 88.78% of the company’s stock.

Insider Activity

In related news, Director John W. Childs purchased 32,700 shares of Biohaven stock in a transaction dated Tuesday, March 4th. The shares were acquired at an average cost of $30.47 per share, for a total transaction of $996,369.00. Following the transaction, the director now directly owns 2,320,571 shares of the company’s stock, valued at approximately $70,707,798.37. This trade represents a 1.43 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 16.00% of the company’s stock.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.